Critical Contrast: Adverum Biotechnologies (NASDAQ:ADVM) versus Vericel (NASDAQ:VCEL)

Share on StockTwits

Adverum Biotechnologies (NASDAQ:ADVM) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Adverum Biotechnologies and Vericel, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adverum Biotechnologies 0 4 3 0 2.43
Vericel 0 1 3 0 2.75

Adverum Biotechnologies currently has a consensus price target of $13.20, suggesting a potential upside of 12.63%. Vericel has a consensus price target of $23.23, suggesting a potential upside of 32.97%. Given Vericel’s stronger consensus rating and higher possible upside, analysts plainly believe Vericel is more favorable than Adverum Biotechnologies.

Volatility & Risk

Adverum Biotechnologies has a beta of 2.76, meaning that its share price is 176% more volatile than the S&P 500. Comparatively, Vericel has a beta of 2.67, meaning that its share price is 167% more volatile than the S&P 500.

Insider and Institutional Ownership

75.5% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 86.9% of Vericel shares are owned by institutional investors. 4.2% of Adverum Biotechnologies shares are owned by insiders. Comparatively, 4.5% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Adverum Biotechnologies and Vericel’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adverum Biotechnologies N/A -33.49% -28.81%
Vericel -12.68% 3.66% 2.73%

Valuation and Earnings

This table compares Adverum Biotechnologies and Vericel’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adverum Biotechnologies $1.61 million 470.18 -$72.63 million ($1.18) -9.93
Vericel $90.86 million 8.59 -$8.14 million ($0.14) -124.79

Vericel has higher revenue and earnings than Adverum Biotechnologies. Vericel is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Adverum Biotechnologies on 9 of the 13 factors compared between the two stocks.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Fiera Capital Corp Invests $1.09 Million in Pinterest
Fiera Capital Corp Invests $1.09 Million in Pinterest
Fiera Capital Corp Sells 468,443 Shares of iShares MSCI Saudi Arabia Capped ETF
Fiera Capital Corp Sells 468,443 Shares of iShares MSCI Saudi Arabia Capped ETF
Yamana Gold Inc.  Senior Officer Richard Campbell Sells 13,050 Shares
Yamana Gold Inc. Senior Officer Richard Campbell Sells 13,050 Shares
Fiera Capital Corp Reduces Holdings in Activision Blizzard, Inc.
Fiera Capital Corp Reduces Holdings in Activision Blizzard, Inc.
Fiera Capital Corp Sells 7,525 Shares of Lincoln Electric Holdings, Inc.
Fiera Capital Corp Sells 7,525 Shares of Lincoln Electric Holdings, Inc.
Vanguard S&P Small-Cap 600 ETF  Stock Holdings Lowered by Fiera Capital Corp
Vanguard S&P Small-Cap 600 ETF Stock Holdings Lowered by Fiera Capital Corp


© 2006-2020 Ticker Report